Live updates



Cancer charity wants drug to be 'routinely available'

Prostate Cancer UK has welcomed the news of a new drug that offers hope to men who have run out of treatment options, but urged other areas of the UK to appraise the drug swiftly.

More than 40,000 men are diagnosed with prostate cancer in the UK every year Credit: Prostate Cancer UK

Drew Lindon, from the charity said: "For some men, this drug could offer precious extra time with loved ones, and will be a welcome addition to what is currently a very limited armoury.

"However, although enzalutamide can now be prescribed by doctors, a man's local NHS health provider is not obliged to pay for it.

"And while men in England can apply for access through the Cancer Drugs Fund, others living elsewhere in the UK could be left at a disadvantage.

"We urge National Institute for Health and Clinical Excellence and Scottish Medicines Consortium to appraise this drug swiftly, and the pharmaceutical company to set a reasonable price, in the hope that it will soon be recommended and routinely available on the NHS for all those men who need it."

Prostate cancer drug 'makes patients feel better'

Managing the side effects of cancer treatment is one of the biggest challenges in medicine, a consultant oncologist at University College London Hospitals said today, after the launch of a new drug with less side effects.

Dr Heather Payne said:

The launch of Xtandi represents a major advance in the treatment of patients with advanced prostate cancer.

One of the biggest challenges in cancer medicine is managing the side effects that come with treatment, so it is remarkable to find a new therapy which makes patients' feel better.

Extending patients' lives at this stage of their disease is our primary aim, but it's incredibly important to balance this with the impact treatment may have on patients' quality of life.

New cancer drug 'positive impact' on quality of life

A new hi-tech prostate cancer drug has already demonstrated a 'positive impact on the quality of life', the Institute of Cancer Research said today, as the treatment trials in the capital.

ITV ran a campaign to encourage women to talk to men about cancer last month.

Professor Johann de Bono from the institute, who led the Affirm trial, said:

"Enzalutamide is a much needed development in prostate cancer treatment and will provide a new option for the increasing number of men with advanced prostate cancer in the UK whose disease has become resistant to first-line hormonal treatments and who have had docetaxel chemotherapy.

"Enzalutamide has already demonstrated a positive impact on quality of life whilst increasing the life-span of patients with this common disease.

"It's use will bring significant benefits, establishing it as a key component of advanced prostate cancer treatment in the UK."

Load more updates